Can ArteraAI Breast turn routine pathology slides into breast cancer risk intelligence?
AI can read pathology slides, but can it change breast cancer treatment decisions? ArteraAI Breast puts that question before clinicians and payers.
AI can read pathology slides, but can it change breast cancer treatment decisions? ArteraAI Breast puts that question before clinicians and payers.
Autonomous labs can run experiments faster. The bigger shift is what happens when biopharma researchers stop executing and start directing.
Digital therapeutics struggled alone. Remepy and Merck KGaA are testing whether software works better when built into the drug itself.
AI can now guide coronary imaging in real time. Abbott’s Ultreon 3.0 puts precision PCI closer to routine clinical workflow.
Phare Bio and Basilea partner to develop an AI-designed antibiotic for deadly gram-negative infections. Explore what this deal could mean for the future of antimicrobial R&D.
Eli Lilly and Indiana University are launching a $40M clinical trial and Alzheimer’s research initiative in Indiana. See what it could mean for U.S. pharma.